Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study of Adebrelimab Plus Apatinib and SOX Regimen for Conversion Therapy of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07353684 is registered in ClinicalTrials.gov with Beijing Friendship Hospital as lead sponsor.

NCT NCT07353684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07353684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study of Adebrelimab Plus Apatinib and SOX Regimen for Conversion Therapy of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Beijing Friendship Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
May 11, 2025
Completion date
May 31, 2028
Enrollment
49 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adebrelimab, adenocarcinoma of ge junction, adenocarcinoma of stomach